Canada markets closed

Relevium Technologies Inc. (RLLVF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0140-0.0048 (-25.53%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0188
Open0.0140
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0140 - 0.0140
52 Week Range0.0140 - 0.0700
Volume1,050
Avg. Volume35,703
Market Cap3.4M
Beta (5Y Monthly)2.56
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Relevium Provides Update on the Exclusive Supply of Medical Examination Gloves
    GlobeNewswire

    Relevium Provides Update on the Exclusive Supply of Medical Examination Gloves

    MONTREAL, May 05, 2021 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), whose primary mandate is to focus on international procurement, logistics, and delivery of Personal Protective Equipment (“PPE) and wellness products, is pleased to provide an update on the performance of the exclusivity contract to supply medical examination gloves for North America. On March 11, 2021 (see Press Release), Relevium announced the procurement and subsequent delivery of the first production batch of Personal Protective Equipment (“PPE”) from a Supply Agreement entered into during the last quarter of 2020 with 24 Clean Energy (the “Supplier”), a manufacturer and distributor of high-end medical grade nitrile gloves. The Company also announced it had obtained the “exclusive” North American rights to market the “DI-Line” brand of medical grade gloves, a much needed and sought-after PPE product. The Thailand based supplier was to commence delivery of the first containers in the month of April 2021. Due to various issues relating to the COVID-19 pandemic, causing delays in the entire international supply chain cycle, the supplier has informed Relevium management to expect the first shipment to be delivered starting in the month of May, with the final delivery to its customers in the month of June. The total number of units to be shipped to the port of Los Angeles is approximately 300,000 boxes (the First Phase) out of a total of 500,000 boxes (total order). The medical examination gloves are to be delivered to healthcare institutions in the United States, and form part of the initial launch of the suppliers “brand” into the North American market. Aurelio Useche, CEO of Relevium stated: “We will continue to closely monitor the execution of this contract, and we expect to deliver a high-value product to our valued customer base. Our distribution partnership with H-Source Holdings provides the Company with access to Hospital Groups across the United States in a safe, highly efficient and complaint delivery platform, which we will continue to leverage as we enroll new clients into our program”. About Relevium TechnologiesRelevium Technologies Inc., is a publicly traded Company, focussed on international procurement, logistics, and delivery of Personal Protective Equipment (“PPE) into the North American marketplace. Utilizing trusted vendors and suppliers, and integrating a comprehensive, state-of-the-art supply chain, Artificial Intelligence (“AI), and Blockchain technology, enables a highly secure and compliant platform for delivery of PPE equipment to Governments, Hospitals, Foundations, and various Institutions. Biocannabix Health Corporation, a wholly owned subsidiary of Relevium Technologies Inc., is focused on Paediatric and Geriatric applications of Cannabinoid nutraceutical and medical food formulations. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and cannabinoids. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking StatementsThis release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor. On Behalf of the Board of Directors RELEVIUM TECHNOLOGIES INC. Aurelio UsechePresident and CEO For more information about this press release: Tel: +1.888.528.8687 RELEVIUM TECHNOLOGIES INCEmail: investors@releviumcorp.com Website: www.releviumtechnologies.com Like us on FacebookFollow us on Twitter Follow us on LinkedIn

  • Biocannabix Enters Into LOI With IAM Health GmbH
    GlobeNewswire

    Biocannabix Enters Into LOI With IAM Health GmbH

    MONTREAL, April 29, 2021 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), and its’ wholly-owned subsidiary, Biocannabix Health Corporation (the “BCX”), a company focused on Paediatric and Geriatric applications of Cannabinoid nutraceutical and medical food formulations, is delighted to announce that it has entered in a Letter of Intent (the “LOI”) with IAM Health GmbH (the “IAM”), a German based Research & Development company, to pursue a number of pre-defined research opportunities. The terms of the LOI will allow Biocannabix to hold a 51% equity interest of the combined research entity and will continue operations under the IAM Health GmbH name, which will become the Company’s brand and driver for clinical and research therapeutics. IAM HEALTH GmbH PARTNERSHIP IAM Health GmbH was founded by a group of multi-disciplinary professionals, combining legal expertise, medical doctors, research and clinical development specialists, and contract manufacturing, to focus on the development of new treatments for autoimmune conditions, including the study of the role of certain cannabinoids, primarily for the development of therapies for pediatric applications. A NEW DIRECTION FOR BIOCANNABIX WITH A FOCUS ON RESEARCH AND DEVELOPMENT The partnership between BCX and IAM was designed to provide continuity to the research the company began in the pediatric cannabinoid space and will leverage the clinical and research capabilities both in Germany and Colombia through its investment in Lifeline Pharma for Nutraceutical and Pharmaceutical development Aurelio Useche, CEO of Relevium stated: “We are extremely pleased to enter into this valued partnership with IAM Health and their team, as we set a new direction for Biocannabix. The partnership in Germany will drive focus and solidify the company’s new direction for the development of proprietary consumer and medical products”. Ms. Nina Wlodarczyk, Managing Director of IAM Health, commented: “We have developed the ideal ecosystem for conducting research and clinical activities that can leverage not only our new infrastructure here in Germany, but also the existing established relationships in Colombia. We are very pleased to join forces with Biocannabix and have great expectations for the current year”. About Relevium TechnologiesRelevium is a publicly traded Company that operates in the health and wellness industry, including cannabinoids, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and cannabinoids. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates in various segments including health, wellness, cannabinoid research and PPE business. About IAM HEALTH GmbHBased in Germany, IAM Health GmbH is a privately owned clinical and research company in the domains of nutraceuticals, and pharmaceuticals seeking for partnerships for the development of innovative, patented nature sourced products. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking StatementsThis release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor. On Behalf of the Board of Directors RELEVIUM TECHNOLOGIES INC. Aurelio UsechePresident and CEO For more information about this press release: Tel: +1.888.528.8687 RELEVIUM TECHNOLOGIES INCEmail: investors@releviumcorp.comWebsite: www.releviumtechnologies.comLike us on FacebookFollow us on TwitterFollow us on LinkedIn

  • Relevium Secures North American Exclusivity for Medical Examination Gloves, with First Shipment to Arrive in Los Angeles by Mid April
    GlobeNewswire

    Relevium Secures North American Exclusivity for Medical Examination Gloves, with First Shipment to Arrive in Los Angeles by Mid April

    MONTREAL, March 11, 2021 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the company has secured delivery of the delivery of first production batch Personal Protective Equipment (“PPE”) from the a supply agreement entered into the last quarter of 2020 with 24 Clean Energy (the “Supplier”), a manufacturer and distributor of high-end medical grade nitrile gloves. Relevium has also obtained the exclusive North American rights to market the “DI-Line” brand of medical grade gloves, a much needed and sought-after PPE product. This initial order of 500,000 boxes, each box containing a 100-unit count, was secured at a cost of just over CAD $5 million, with funds being paid in advance at the time of order. The supplier has finished the first production run and the gloves are expected to arrive at the port of Los Angeles during the third week of April. The Company will deliver the gloves to its customers in the US in conjunction with its Canadian distribution partners. The Company expects revenues from the 500,000 boxes to be of a total transactional value of between CAD $8 and $10 million. According to market research company Grand View, in 2019, prior to the pandemic, the global nitrile gloves market size was valued at USD 3.12 Billion, with an expected compounded annual growth rate (CAGR) of 14.1% from 2020 to 2027, not including the effect of the current pandemic. Rising awareness regarding the benefits of the PPE product in healthcare facilities, coupled with the recent COVID-19 pandemic, are expected to accelerate the long-term demand, and in particular as health agencies in Europe review proposals for making the use of nitrile gloves mandatory in the services and institutional industries as well. Aurelio Useche, CEO of Relevium stated, “We see a long-term incremental demand for health care PPE and related products, a natural fit to our existing core, which will be channeled in conjunction with the H-Source Platform. We proactively capture the opportunity created by a major gap in the demand and supply of this commodity leaving users looking for a stable supply chain. We expect the imbalance to remain strong throughout 2021 and prices to remain elevated”. Mr. Useche further comments: “We have now secured direct access to PPE manufactures & suppliers, which has established significant credibility with our valued customers. By collaborating with our trusted partner H-Source Holdings (TSXV: HSI), we can now deploy an entire end-to-end solution, including procurement, logistics & supply-chain delivery, all backed by block-chain technology. This provides Relevium a significant advantage for existing and future opportunities in the PPE / medical sectors, both in North America and globally”. About Relevium TechnologiesRelevium is a publicly traded Company that operates in the health and wellness industry, including cannabinoids, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and cannabinoids. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries: BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com. Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical Company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking StatementsThis release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor. On Behalf of the Board of Directors RELEVIUM TECHNOLOGIES INC. Aurelio UsechePresident and CEO For more information about this press release: Tel: +1.888.528.8687 RELEVIUM TECHNOLOGIES INCEmail: investors@releviumcorp.com Website: www.releviumtechnologies.com Like us on FacebookFollow us on Twitter Follow us on LinkedIn